Xilio Therapeutics is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The company is using its proprietary geographically precise solutions (GPS) platform to rapidly engineer novel molecules, including cytokines and other biologics, that are designed to optimize their therapeutic index. Xilio Therapeutics is building a pipeline of tumor-selective, GPS-enabled cytokine and checkpoint inhibitor molecules designed to localize activity within the tumor microenvironment without systemic effect, resulting in the potential to achieve enhanced anti-tumor activity.
Recent Press Releases
January 20, 2022
Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors
January 6, 2022
December 2, 2021
Data Provided by Refinitiv. Minimum 15 minutes delayed.